Opsidio Announces First Patient Dosed in Phase 2a Trial of OpSCF in Moderate to Severe Atopic Dermatitis - OpSCF is a novel monoclonal antibody directed against the inflammatory form of stem cell factor See more here
Read More
Opsidio Closes Bridge Financing to Develop Monoclonal Antibodies to Treat Fibrotic Diseases See more here
Read More